Supernus Pharmaceuticals Inc. Common Stock (SUPN)

FairStock Score: 41/100 — MIXED

Key Financials

Strengths

• Generates $133 million in annual free cash flow (4.6% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.04, providing financial flexibility
• Altman Z-Score of 5.4 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 21.5% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration

AI Analysis

Supernus Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $2.9 billion. Revenue stands at $777 million, though the company is currently unprofitable. From a quality standpoint, Supernus shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 5.4 confirms fortress-level solvency. On valuation, the stock is 0.7% FCF yield. Growth dynamics show revenue growing at 21.5% and profit growth of -126.8%. Our composite FairStock Score of 41/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Supernus's 21% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $133 million in annual free cash flow (4.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer